{
    "eid": "2-s2.0-85060988754",
    "title": "Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis",
    "cover-date": "2018-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Biochemistry, Genetics and Molecular Biology (all)",
            "@code": "1300",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "Fatty liver",
        "Fatty liver disease",
        "HMG-CoA",
        "Hydroxymethylglutaryl-CoA reductase inhibitors",
        "Non-alcoholic",
        "Statins",
        "Steatohepatitis"
    ],
    "authors": [
        "Pakkapon Rattanachaisit",
        "Paweena Susantitaphong",
        "Kessarin Thanapirom",
        "Roongruedee Chaiteerakij",
        "Piyawat Komolmit",
        "Pisit Tangkijvanich",
        "Sombat Treeprasertsuk"
    ],
    "citedby-count": 4,
    "ref-count": 69,
    "ref-list": [
        "The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases",
        "Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis",
        "Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis",
        "Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups",
        "Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis",
        "Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions",
        "Design and validation of a histological scoring system for nonalcoholic fatty liver disease",
        "ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions",
        "Meta-analysis in clinical trials",
        "Assessing heterogeneity in meta-analysis: Q statistic or I2 index?",
        "Bias in meta-analysis detected by a simple, graphical test",
        "Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study",
        "Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study",
        "Efficacy of rosuvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia: An open-label, pilot study",
        "Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-\u03b1-lowering property",
        "Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome",
        "A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial",
        "Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis",
        "Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C",
        "Statin therapy and serum transaminases among a cohort of HCV-infected veterans",
        "Statin use in patients with cirrhosis: A retrospective cohort study",
        "Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES",
        "Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection",
        "Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease",
        "Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial",
        "A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients",
        "Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis",
        "Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: A randomised study",
        "Paraoxonase-1 activity, malondi-aldehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin",
        "Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients",
        "Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: A retrospective study",
        "Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St Francis Heart Study randomized clinical trial",
        "Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease",
        "Hepatic effects of lovastatin exposure in patients with liver disease: A retrospective cohort study",
        "Statin use and non-alcoholic steatohepatitis in at risk individuals",
        "Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis",
        "Pravastatin in patients with nonalcoholic steatohepatitis: Results of a pilot study",
        "Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study",
        "Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: Clinical usefulness of AGEs as a biomarker for the attenuation of NASH",
        "Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia",
        "What\u2019s new in liver fibrosis? The origin of myofibroblasts in liver fibrosis",
        "Mechanisms of fibrogenesis",
        "Statins and cancer: A systematic review and meta-analysis",
        "Lovastatin-mediated G1arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase",
        "Liver cirrhosis",
        "Antimicrobial and immunomodulatory attributes of statins: Relevance in solid-organ transplant recipients",
        "Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis",
        "Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes",
        "Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats",
        "Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome",
        "Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis",
        "Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism",
        "Statins, Rho GTPases and KLF2: New mechanistic insight into liver fibrosis and portal hypertension",
        "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies",
        "Pharmacological actions of statins: A critical appraisal in the management of cancer",
        "Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholeste-rolaemic haemodialysis patients",
        "Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis",
        "Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis",
        "The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease",
        "Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins",
        "Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians",
        "Safety of statin therapy in patients with preexisting liver disease",
        "The potential role of statins in treating liver disease",
        "Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: Post-hoc analysis of a randomized trial",
        "Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercho-lesterolemia and mild to moderate hepatic damage)",
        "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease",
        "Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update",
        "Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60031780",
            "affilname": "Thai Red Cross Agency",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031780",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "NAFLD",
        "Department of Medicine, Chulalongkorn University"
    ]
}